Pengenalan
Halaman ini menyediakan analisis menyeluruh tentang sejarah dagangan orang dalam yang diketahui Brian H Dovey. Orang dalam ialah pegawai, pengarah atau pelabur penting dalam syarikat. Adalah haram bagi orang dalam untuk membuat perdagangan dalam syarikat mereka berdasarkan maklumat khusus bukan awam. Ini tidak bermakna haram bagi mereka untuk membuat sebarang perdagangan dalam syarikat mereka sendiri. Tetapi mereka mesti melaporkan semua perdagangan kepada SEC melalui Borang 4. Walaupun terdapat sekatan ini, penyelidikan akademik menunjukkan bahawa orang dalam - secara amnya - cenderung untuk mengatasi prestasi pasaran dalam syarikat mereka sendiri.
Purata Keuntungan Perdagangan
Purata keuntungan perdagangan ialah purata pulangan semua pembelian pasaran terbuka yang dibuat oleh orang dalam dalam tempoh tiga tahun terakhir. Untuk mengira ini, kami memeriksa setiap pembelian pasaran terbuka yang tidak dirancang oleh orang dalam, tidak termasuk semua dagangan yang ditandakan sebagai sebahagian daripada pelan dagangan 10b5-1. Kami kemudian mengira prestasi purata dagangan tersebut sepanjang 3, 6 dan 12 bulan, dengan purata setiap tempoh tersebut untuk menjana metrik prestasi akhir bagi setiap dagangan. Akhir sekali, kami puratakan semua metrik prestasi untuk mengira metrik prestasi untuk orang dalam. Senarai ini hanya termasuk orang dalam yang telah membuat sekurang-kurangnya tiga dagangan dalam dua tahun lepas.
Jika keuntungan berdagang orang dalam ini ialah "N/A", maka orang dalam sama ada tidak membuat sebarang pembelian pasaran terbuka dalam tempoh tiga tahun terakhir, atau dagangan yang mereka buat adalah terlalu baru untuk mengira metrik prestasi yang boleh dipercayai.
Kekerapan Kemas Kini: Harian
Syarikat dengan Kedudukan Orang Dalam yang Dilaporkan
Pemfailan SEC menunjukkan Brian H Dovey telah melaporkan pegangan atau perdagangan dalam syarikat berikut:
Bagaimana Mentafsir Carta
Carta berikut menunjukkan prestasi saham sekuriti selepas setiap dagangan pasaran terbuka dan tidak dirancang yang dibuat oleh Brian H Dovey. Perdagangan tidak dirancang ialah dagangan yang tidak dibuat sebagai sebahagian daripada pelan dagangan 10b5-1. Prestasi saham dicatatkan sebagai perubahan peratus kumulatif dalam harga saham. Sebagai contoh, jika perdagangan orang dalam dibuat pada 1 Januari 2019, carta akan menunjukkan perubahan peratusan harian sekuriti kepada hari ini. Jika harga saham naik dari $10 kepada $15 pada masa ini, perubahan peratus terkumpul dalam harga saham ialah 50%. Perubahan dalam harga daripada $10 kepada $20 ialah 100% dan perubahan dalam harga $10 hingga $5 ialah -50%.
Secara dasarnya, kami cuba untuk menentukan sejauh mana dagangan orang dalam berkait rapat dengan pulangan berlebihan (positif atau negatif) dalam harga saham untuk melihat sama ada orang dalam menetapkan masa dagangan mereka untuk mendapat keuntungan daripada maklumat orang dalam. Pertimbangkan situasi di mana orang dalam melakukan perkara ini. Dalam keadaan ini, kami menjangkakan sama ada (a) pulangan positif selepas pembelian, atau (b) pulangan negatif selepas jualan. Dalam kes (a), carta PEMBELIAN akan menunjukkan satu siri keluk condong ke atas, menunjukkan pulangan positif selepas setiap transaksi pembelian. Dalam kes (b), carta JUALAN akan menunjukkan satu siri keluk condong ke bawah, menunjukkan pulangan negatif selepas setiap transaksi jualan.
Walau bagaimanapun, ini sahaja tidak cukup untuk membuat kesimpulan. Jika, sebagai contoh, harga saham syarikat berada dalam pendakian bukan disebabkan kitaran selama bertahun-tahun, maka kami menjangkakan semua plot selepas pembelian akan condong ke atas. Begitu juga, kemerosotan bukan disebabkan kitaran selama bertahun-tahun akan mengakibatkan plot pasca perdagangan condong ke bawah. Kedua-dua carta ini tidak akan mencadangkan aktiviti perdagangan orang dalam.
Penunjuk terkuat ialah keadaan di mana harga saham adalah sangat kitaran, dan terdapat kedua-dua isyarat positif dalam carta PEMBELIAN dan plot negatif pada carta JUALAN. Situasi ini akan sangat menunjukkan orang dalam yang menentukan masa perdagangan untuk kelebihan kewangan mereka.
Pembelian Orang Dalam ADYX / Adynxx, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam ADYX / Adynxx, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam ALDX / Aldeyra Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam ALDX / Aldeyra Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam ATRA / Atara Biotherapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam ATRA / Atara Biotherapeutics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam ATYR / aTyr Pharma, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam ATYR / aTyr Pharma, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam BNGO / Bionano Genomics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-08-23 | BNGO | Domain Partners VIII, L.P. | 15,000 | 6.1250 | 429 | 214.3750 | 91,875 | 35 | 82.5 | -56,565 | -61.57 |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam BNGO / Bionano Genomics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam ESPR / Esperion Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2014-10-21 | ESPR | DOMAIN PARTERS VII L P | 500,000 | 20.0000 | 500,000 | 20.0000 | 10,000,000 | 210 | 115.3000 | 47,650,000 | 476.50 |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam ESPR / Esperion Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam EVOK / Evoke Pharma, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam EVOK / Evoke Pharma, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam GKOS / Glaukos Corporation - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam GKOS / Glaukos Corporation - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam SNDX / Syndax Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam SNDX / Syndax Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Pembelian Orang Dalam VCYT / Veracyte, Inc. - Analisis Keuntungan Jangka Pendek
Dalam bahagian ini, kami menganalisis keuntungan setiap pembelian orang dalam pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Analisis ini membantu untuk memahami sama ada orang dalam secara konsisten menjana pulangan tidak normal dan patut diikuti. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah bersifat teori .
Jadual berikut menunjukkan pembelian pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Maks |
Harga pada Maks |
Maks Keuntungan ($) |
Pulangan Maks (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Jualan Orang Dalam VCYT / Veracyte, Inc. - Analisis Kerugian Jangka Pendek
Dalam bahagian ini, kami menganalisis pengelakan kerugian jangka pendek bagi setiap jualan dalaman pasaran terbuka yang tidak dirancang yang dibuat dalam ADYX / Adynxx, Inc.. Corak pengelakan kerugian yang konsisten mungkin mencadangkan bahawa urus niaga jualan masa hadapan mungkin meramalkan penurunan harga. Analisis ini adalah untuk satu tahun selepas setiap perdagangan, dan hasilnya adalah teori .
Jadual berikut menunjukkan jualan pasaran terbuka terkini yang bukan sebahagian daripada pelan dagangan automatik.
Tarikh Dagangan | Simbol Saham | Orang dalam | Saham Dilaporkan |
Harga Dilaporkan |
Saham Dilaraskan |
Harga Dilaraskan |
Asas Kos | Hari ke Min |
Harga pada Min |
Kerugian Maks Dielakkan ($) |
Kerugian Maks Dielakkan (%) |
---|---|---|---|---|---|---|---|
Tiada dagangan pasaran terbuka tidak dirancang yang tidak diketahui untuk gabungan orang dalam dan sekuriti ini |
Harga Larasan ialah harga larasan berpecah. Saham Larasan ialah saham terlaras berpecah.
Sejarah Dagangan Orang Dalam
Jadual ini menunjukkan senarai lengkap dagangan orang dalam yang dibuat oleh Brian H Dovey seperti yang didedahkan kepada Suruhanjaya Bursa Sekuriti (SEC).
Tarikh Fail | Tarikh Tran | Borang | Simbol Saham | Sekuriti | Kod | Saham | Baki Saham | Peratus Ubah |
Saham harga |
Tran Nilai |
Baki Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-11-13 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
S - Sale | -85,186 | 0 | -100.00 | ||||
2019-11-13 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
S - Sale | -3,606,002 | 0 | -100.00 | ||||
2019-11-13 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
S - Sale | -15,500 | 0 | -100.00 | 0.00 | -2 | ||
2019-11-13 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
S - Sale | -15,500 | 0 | -100.00 | 0.00 | -2 | ||
2019-08-08 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Warrants to Purchase Common Stock |
P - Purchase | 187,500 | 187,500 | 4.00 | 750,000 | 750,000 | ||
2019-08-08 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
P - Purchase | 250,000 | 813,433 | 44.37 | 4.00 | 1,000,000 | 3,253,732 | |
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Warrants to Purchase Common Stock |
P - Purchase | 15,000 | 15,000 | |||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B Preferred Stock |
C - Conversion | -6,810,098 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D-1 Preferred Stock |
C - Conversion | -3,682,919 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D Preferred Stock |
C - Conversion | -6,396,105 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series C Preferred Stock |
C - Conversion | -5,426,808 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B-1 Preferred Stock |
C - Conversion | -2,986,762 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
P - Purchase | 15,000 | 943,878 | 1.61 | 6.12 | 91,875 | 5,781,253 | |
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 337,694 | 929,878 | 57.03 | 4.59 | 1,550,015 | 4,268,140 | |
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 591,184 | 591,184 | |||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B Preferred Stock |
C - Conversion | -50,532 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D-1 Preferred Stock |
C - Conversion | -27,328 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D Preferred Stock |
C - Conversion | -47,460 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series C Preferred Stock |
C - Conversion | -40,268 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B-1 Preferred Stock |
C - Conversion | -22,161 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 2,505 | 6,891 | 57.11 | 4.59 | 11,498 | 31,630 | |
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 4,386 | 4,386 | |||||
2018-08-27 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
P - Purchase | 1,648,359 | 5,634,329 | 41.35 | 1.82 | 3,000,013 | 10,254,479 | |
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-07-03 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
J - Other | 3,000 | 15,500 | 24.00 | ||||
2018-07-03 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
J - Other | -3,000 | 15,500 | -16.22 | ||||
2018-05-18 |
|
4 | RVA |
REVA Medical, Inc.
Stock Option (Right to Buy) |
A - Award | 25,000 | 25,000 | |||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
C - Conversion | -368 | 0 | -100.00 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
A - Award | 282 | 25,730 | 1.11 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 12,444 | 25,448 | 95.69 | 3.19 | 39,696 | 81,179 | |
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
C - Conversion | -49,632 | 0 | -100.00 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
A - Award | 37,890 | 3,469,029 | 1.10 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 1,678,432 | 3,431,139 | 95.76 | 3.19 | 5,354,198 | 10,945,333 | |
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -988,285 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -47,963 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -15,731 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Warrant to Purchase Common Stock |
D - Sale to Issuer | -20,150 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Warrant to Purchase Common Stock |
D - Sale to Issuer | -20,150 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -1,857,036 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -7,333 | 0 | -100.00 | ||||
2017-07-27 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
J - Other | 5,000 | 12,500 | 66.67 | ||||
2017-07-27 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
J - Other | -5,000 | 18,500 | -21.28 | ||||
2017-07-18 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 5,000 | 5,000 | |||||
2017-07-11 |
|
4 | RVA |
REVA Medical, Inc.
Stock Option (Right to Buy) |
A - Award | 10,500 | 10,500 | |||||
2017-07-11 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
A - Award | 6,000 | 23,500 | 34.29 | ||||
2017-04-12 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
P - Purchase | 49,632 | 49,632 | 100.00 | 4,963,200 | 4,963,200 | ||
2017-04-12 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
P - Purchase | 368 | 368 | 100.00 | 36,800 | 36,800 | ||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 17,695 | 0 | -100.00 | ||||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 1,071 | 0 | -100.00 | ||||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 1,996 | 0 | -100.00 | ||||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -38,094 | 0 | -100.00 | 28.35 | -1,079,965 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -3,553,322 | 0 | -100.00 | 28.35 | -100,736,679 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -47,613 | 0 | -100.00 | 28.35 | -1,349,829 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -1,657 | 0 | -100.00 | 28.35 | -46,976 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -285,679 | 0 | -100.00 | 28.35 | -8,099,000 | ||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -14,271 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -20,583 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series A Preferred Stock |
C - Conversion | -11,083 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
C - Conversion | 49,570 | 49,570 | |||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series E Preferred Stock |
C - Conversion | -482,326 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -597,207 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -836,722 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -1,206,836 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series A Preferred Stock |
C - Conversion | -649,835 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
C - Conversion | 3,985,970 | 3,985,970 | |||||
2016-09-13 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
J - Other | -1,943,109 | 0 | -100.00 | ||||
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -129 | 3,039 | -4.07 | 8.15 | -1,051 | 24,768 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -32 | 3,168 | -1.00 | 8.71 | -279 | 27,593 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -84 | 3,200 | -2.56 | 8.82 | -741 | 28,224 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -81,094 | 1,943,109 | -4.01 | 8.15 | -660,916 | 15,836,338 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -19,718 | 2,024,203 | -0.96 | 8.71 | -171,744 | 17,630,808 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -52,216 | 2,043,921 | -2.49 | 8.82 | -460,545 | 18,027,383 | |
2016-08-01 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
J - Other | 7,500 | 7,500 | |||||
2016-08-01 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
J - Other | -7,500 | 17,500 | -30.00 | ||||
2016-07-14 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 15,000 | 15,000 | |||||
2016-05-27 |
|
4 | RVA |
REVA Medical, Inc.
Stock Option (Right to Buy) |
A - Award | 11,800 | 11,800 | |||||
2016-05-27 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
A - Award | 10,000 | 25,000 | 66.67 | ||||
2016-05-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -5,880 | 10,328 | -36.28 | 4.70 | -27,636 | 48,542 | |
2016-05-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -344,120 | 606,283 | -36.21 | 4.70 | -1,617,364 | 2,849,530 | |
2016-05-02 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -149,765 | 2,096,137 | -6.67 | 6.96 | -1,042,364 | 14,589,114 | |
2016-05-02 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -235 | 3,284 | -6.68 | 6.96 | -1,636 | 22,857 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -61 | 16,208 | -0.37 | 5.02 | -306 | 81,364 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -21 | 16,269 | -0.13 | 5.20 | -109 | 84,599 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -3,603 | 950,403 | -0.38 | 5.02 | -18,087 | 4,771,023 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -1,492 | 954,006 | -0.16 | 5.20 | -7,758 | 4,960,831 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -76 | 16,290 | -0.46 | 5.29 | -402 | 86,174 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -632 | 16,366 | -3.72 | 5.36 | -3,388 | 87,722 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -4,424 | 955,498 | -0.46 | 5.29 | -23,403 | 5,054,584 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -37,054 | 959,922 | -3.72 | 5.36 | -198,609 | 5,145,182 | |
2016-04-13 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -75 | 16,998 | -0.44 | 5.22 | -392 | 88,730 | |
2016-04-13 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -4,348 | 996,976 | -0.43 | 5.22 | -22,697 | 5,204,215 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -251 | 17,073 | -1.45 | 5.35 | -1,343 | 91,341 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -475 | 17,324 | -2.67 | 5.26 | -2,498 | 91,124 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -148 | 17,799 | -0.82 | 5.22 | -773 | 92,911 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -14,554 | 1,001,324 | -1.43 | 5.35 | -77,864 | 5,357,083 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -27,781 | 1,015,878 | -2.66 | 5.26 | -146,128 | 5,343,518 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -8,669 | 1,043,659 | -0.82 | 5.22 | -45,252 | 5,447,900 | |
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -360,640 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -400,422 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 761,062 | 761,062 | |||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -2,674 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -2,967 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 5,641 | 5,641 | |||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -13,925 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 13,925 | 13,925 | |||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -444,460 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -1,299,394 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 1,743,854 | 1,743,854 | |||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2015-08-20 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -11,836 | 1,052,328 | -1.11 | 7.02 | -83,089 | 7,387,343 | |
2015-08-20 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -202 | 17,947 | -1.11 | 7.02 | -1,418 | 125,988 | |
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series F Preferred Stock |
C - Conversion | -286,983 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series E Preferred Stock |
C - Conversion | -589,100 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 876,083 | 876,083 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series F Preferred Stock |
C - Conversion | -2,130 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series E Preferred Stock |
C - Conversion | -4,371 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 6,501 | 6,501 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Warrant |
M - Exercise | -20,470 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series D Preferred Stock |
C - Conversion | -105,128 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series C Preferred Stock |
C - Conversion | -440,178 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series B Preferred Stock |
C - Conversion | -925,926 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series A Preferred Stock |
C - Conversion | -585,958 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
F - Taxes | -8,700 | 2,068,960 | -0.42 | 18.00 | -156,600 | 37,241,280 | |
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
M - Exercise | 20,470 | 2,077,660 | 1.00 | 7.65 | 156,596 | 15,894,099 | |
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 2,057,190 | 2,057,190 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series A Preferred Stock |
C - Conversion | -14,041 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 14,041 | 14,041 | |||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-10 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 50,000 | 50,000 | |||||
2015-05-29 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
A - Award | 15,000 | 15,000 | |||||
2015-05-29 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
J - Other | 32,745 | 32,745 | |||||
2015-05-29 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
J - Other | -250,000 | 1,329,323 | -15.83 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -887,073 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Preferred Stock |
C - Conversion | -1,506,901 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Preferred Stock |
C - Conversion | -12,143,933 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 1,807,820 | 1,807,820 | |||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -6,581 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Preferred Stock |
C - Conversion | -11,182 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Preferred Stock |
C - Conversion | -90,110 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 13,414 | 13,414 | |||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1,565 | 0 | -100.00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -1,954 | 0 | -100.00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 3,519 | 3,519 | |||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -464,756 | 0 | -100.00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -939,289 | 0 | -100.00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -798,188 | 0 | -100.00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 2,202,233 | 2,245,902 | 5,043.01 | ||||
2015-05-06 |
|
4 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
J - Other | 36,187 | 38,094 | 1,897.59 | ||||
2015-05-06 |
|
4 | TBRA |
Regado Biosciences Inc
Common Stock |
P - Purchase | 277,777 | 3,553,322 | 8.48 | 10.62 | 2,949,992 | 37,736,280 | |
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -32,411 | 1,064,164 | -2.96 | 7.07 | -229,146 | 7,523,639 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -7,920 | 1,096,575 | -0.72 | 7.58 | -60,034 | 8,312,038 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -9,832 | 1,104,495 | -0.88 | 7.78 | -76,493 | 8,592,971 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -554 | 18,149 | -2.96 | 7.07 | -3,917 | 128,313 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -135 | 18,703 | -0.72 | 7.58 | -1,023 | 141,769 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -168 | 18,838 | -0.88 | 7.78 | -1,307 | 146,560 | |
2015-03-24 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -350,000 | 2,216,935 | -13.63 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -2,827 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -1,570 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -102,282 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -36,913 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -104,247 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -12,578 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -1,725 | 48,025 | -3.47 | 14.00 | -24,150 | 672,350 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 2,827 | 49,750 | 6.02 | 8.54 | 24,143 | 424,865 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -958 | 46,923 | -2.00 | 14.00 | -13,412 | 656,922 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 1,570 | 47,881 | 3.39 | 8.54 | 13,408 | 408,904 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 46,311 | 46,311 | |||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -165,790 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -92,105 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -7,252,144 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2,164,305 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -6,111,968 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -737,422 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
P - Purchase | 70,000 | 3,091,643 | 2.32 | 14.00 | 980,000 | 43,283,002 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -101,132 | 3,021,643 | -3.24 | 14.00 | -1,415,848 | 42,303,002 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 165,790 | 3,122,775 | 5.61 | 8.54 | 1,415,847 | 26,668,498 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -56,185 | 2,956,985 | -1.86 | 14.00 | -786,590 | 41,397,790 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 92,105 | 3,013,170 | 3.15 | 8.54 | 786,577 | 25,732,472 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 2,921,065 | 2,921,065 | |||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -165,790 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -92,105 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -7,252,144 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2,164,305 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -6,111,968 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -737,422 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
P - Purchase | 70,000 | 3,091,642 | 2.32 | 14.00 | 980,000 | 43,282,988 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -101,132 | 3,021,642 | -3.24 | 14.00 | -1,415,848 | 42,302,988 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 165,790 | 3,122,774 | 5.61 | 8.54 | 1,415,847 | 26,668,490 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -56,185 | 2,956,984 | -1.86 | 14.00 | -786,590 | 41,397,776 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 92,105 | 3,013,169 | 3.15 | 8.54 | 786,577 | 25,732,463 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 2,921,064 | 2,921,064 | |||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -2,827 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -1,570 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -102,282 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -36,913 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -104,247 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -12,578 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -1,725 | 48,023 | -3.47 | 14.00 | -24,150 | 672,322 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 2,827 | 49,748 | 6.03 | 8.54 | 24,143 | 424,848 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -958 | 46,921 | -2.00 | 14.00 | -13,412 | 656,894 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 1,570 | 47,879 | 3.39 | 8.54 | 13,408 | 408,887 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 46,309 | 46,309 | |||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -6,250 | 0 | -100.00 | ||||
2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -22,306 | 0 | -100.00 | ||||
2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -3,006,132 | 0 | -100.00 | ||||
2014-10-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 500,000 | 2,566,935 | 24.19 | 20.00 | 10,000,000 | 51,338,700 | |
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -4,606 | 0 | -100.00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -9,443 | 0 | -100.00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
P - Purchase | 1,841 | 15,890 | 13.10 | 11.00 | 20,251 | 174,790 | |
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
C - Conversion | 14,049 | 14,049 | |||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -620,776 | 0 | -100.00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1,272,607 | 0 | -100.00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
P - Purchase | 248,159 | 2,141,542 | 13.11 | 11.00 | 2,729,749 | 23,556,962 | |
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
C - Conversion | 1,893,383 | 1,893,383 | |||||
2014-09-12 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
J - Other | -300,000 | 2,763,294 | -9.79 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -502 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
F - Taxes | -1,386 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -6,866 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series B Preferred Stock |
C - Conversion | -3,238 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
F - Taxes | -277 | 11,715 | -2.31 | 16.00 | -4,432 | 187,440 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
M - Exercise | 502 | 11,992 | 4.37 | 8.79 | 4,413 | 105,410 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 11,490 | 11,490 | |||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -67,755 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
F - Taxes | -186,828 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -925,479 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series B Preferred Stock |
C - Conversion | -436,485 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
F - Taxes | -37,224 | 1,579,323 | -2.30 | 16.00 | -595,584 | 25,269,168 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
M - Exercise | 67,755 | 1,616,547 | 4.37 | 8.79 | 595,566 | 14,209,448 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 1,548,792 | 1,548,792 | |||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -1,165 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -7,043 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -8,792 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 17,000 | 17,000 | |||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -579,630 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -657,192 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -820,320 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 419,744 | 2,476,886 | 20.40 | 8.00 | 3,357,952 | 19,815,088 | |
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 2,057,142 | 2,057,142 | |||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-06-30 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 50,000 | 50,000 | |||||
2014-05-14 |
|
4 | RVA |
REVA Medical, Inc.
Stock Option (Right to Buy) |
A - Award | 15,000 | 15,000 | |||||
2014-05-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2014-05-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 21,250 | 1,973,389 | 1.09 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3,882 | 0 | -100.00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 9,208 | 9,208 | |||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock Warrant (Right to Buy) |
M - Exercise | -60,576 | 0 | -100.00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock Warrant (Right to Buy) |
M - Exercise | -60,576 | 0 | -100.00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -755,263 | 0 | -100.00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -486,316 | 0 | -100.00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
F - Taxes | -39,063 | 1,952,139 | -1.96 | 8.00 | -312,504 | 15,617,112 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
F - Taxes | -39,063 | 1,952,139 | -1.96 | 8.00 | -312,504 | 15,617,112 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
M - Exercise | 60,576 | 1,991,202 | 3.14 | 5.16 | 312,572 | 10,274,602 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
M - Exercise | 60,576 | 1,991,202 | 3.14 | 5.16 | 312,572 | 10,274,602 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 1,909,113 | 1,909,113 | |||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-04-23 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Warrant to Purchase Common Stock |
M - Exercise | -7,882 | 0 | -100.00 | ||||
2014-04-23 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Warrant to Purchase Common Stock |
M - Exercise | -461,265 | 0 | -100.00 | ||||
2014-04-23 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Common Stock |
F - Taxes | -15 | 129,448 | -0.01 | 5.30 | -80 | 686,074 | |
2014-04-23 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Common Stock |
M - Exercise | 78,820 | 129,463 | 155.64 | 0.00 | 79 | 129 | |
2014-04-23 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Common Stock |
F - Taxes | -871 | 7,579,194 | -0.01 | 5.30 | -4,616 | 40,169,728 | |
2014-04-23 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Common Stock |
M - Exercise | 4,612,650 | 7,580,065 | 155.44 | 0.00 | 4,613 | 7,580 | |
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -27,500 | 0 | -100.00 | 14.00 | -385,000 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -78,369 | 0 | -100.00 | 14.00 | -1,097,166 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -7,313,241 | 0 | -100.00 | 14.00 | -102,385,374 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -50,743 | 0 | -100.00 | 14.00 | -710,402 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -2,972,678 | 0 | -100.00 | 14.00 | -41,617,492 | ||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series D Preferred Stock |
C - Conversion | -7,430 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series C Preferred Stock |
C - Conversion | -15,799 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series B Preferred Stock |
C - Conversion | -10,661 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series D Preferred Stock |
C - Conversion | -435,663 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series C Preferred Stock |
C - Conversion | -926,321 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series B Preferred Stock |
C - Conversion | -625,065 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
C - Conversion | 33,890 | 33,890 | |||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
C - Conversion | 1,987,049 | 1,987,049 | |||||
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -1,367,020 | 0 | -100.00 | ||||
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
F - Taxes | -765,532 | 2,972,678 | -20.48 | 14.00 | -10,717,448 | 41,617,492 | |
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1,367,020 | 3,738,210 | 57.65 | 7.84 | 10,717,437 | 29,307,566 | |
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -23,317 | 0 | -100.00 | ||||
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
F - Taxes | -13,058 | 50,743 | -20.47 | 14.00 | -182,812 | 710,402 | |
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
M - Exercise | 23,317 | 63,801 | 57.60 | 7.84 | 182,805 | 500,200 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | 156 | 156 | |||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | -156 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -9,469 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -3,535 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | 21,041 | 21,041 | |||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | -21,041 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -1,276,243 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -476,464 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 13,004 | 13,004 | |||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 1,752,707 | 1,752,707 | |||||
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -2,230 | 34,907 | -6.00 | 6.56 | -14,629 | 228,990 |
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -1,010 | 37,137 | -2.65 | 6.01 | -6,070 | 223,193 |
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -204,315 | 3,590,931 | -5.38 | 6.56 | -1,340,306 | 23,556,507 |
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -92,445 | 3,795,246 | -2.38 | 6.01 | -555,594 | 22,809,428 |
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Common Stock |
J - Other | 6,008 | 6,008 | |||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Series D Preferred Stock |
J - Other | -10,068 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series D Preferred Stock |
C - Conversion | -38,941 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series C Preferred Stock |
C - Conversion | -9,378 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series B Preferred Stock |
C - Conversion | -6,071 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Common Stock |
J - Other | 352,351 | 352,351 | |||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Series D Preferred Stock |
J - Other | -590,403 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series D Preferred Stock |
C - Conversion | -2,283,114 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series C Preferred Stock |
C - Conversion | -549,833 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series B Preferred Stock |
C - Conversion | -356,111 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Common Stock |
C - Conversion | 54,390 | 54,390 | |||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Common Stock |
C - Conversion | 3,189,058 | 3,189,058 | |||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series C Preferred Stock |
C - Conversion | -5,053 | 0 | -100.00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series C Preferred Stock |
C - Conversion | -680,972 | 0 | -100.00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series B Preferred Stock |
C - Conversion | -17,677 | 0 | -100.00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series B Preferred Stock |
C - Conversion | -2,382,322 | 0 | -100.00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
C - Conversion | 22,730 | 22,730 | |||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
C - Conversion | 3,063,294 | 3,063,294 | |||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Series A Preferred Stock |
C - Conversion | -19,006 | 0 | -100.00 | ||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Series A Preferred Stock |
C - Conversion | -1,114,327 | 0 | -100.00 | ||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
C - Conversion | 19,006 | 19,006 | |||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
C - Conversion | 1,114,327 | 1,114,327 | |||||
2013-09-24 | 3 | EVOK |
Evoke Pharma Inc
Common Stock |
5,250 | ||||||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series D Preferred Stock |
C - Conversion | -7,407 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series C Preferred Stock |
C - Conversion | -2,899 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series B Preferred Stock |
C - Conversion | -4,233 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series E Preferred Stock |
C - Conversion | -225,913 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series D Preferred Stock |
C - Conversion | -894,120 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series C Preferred Stock |
C - Conversion | -270,568 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series B Preferred Stock |
C - Conversion | -394,969 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 7,407 | 14,920 | 98.59 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 2,899 | 7,513 | 62.83 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 4,233 | 4,614 | 1,111.02 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
P - Purchase | 750,000 | 2,571,117 | 41.18 | 4.00 | 3,000,000 | 10,284,468 | |
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 225,913 | 1,821,117 | 14.16 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 894,120 | 1,595,204 | 127.53 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 270,568 | 701,084 | 62.85 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 394,969 | 430,516 | 1,111.12 | ||||
2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
35,547 | ||||||||
2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
381 | ||||||||
2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
17,171 | ||||||||
2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 331,873 | 1,857,036 | 21.76 | 6.03 | 1,999,999 | 11,191,242 | |
2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 7,333 | 7,333 | 6.03 | 44,192 | 44,192 | ||
2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 988,285 | 988,285 | 6.03 | 5,955,801 | 5,955,801 | ||
2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
47,963 | ||||||||
2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
1,525,163 | ||||||||
2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
15,731 | ||||||||
2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 331,873 | 1,897,336 | 21.20 | 6.03 | 1,999,999 | 11,434,106 | |
2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 7,333 | 7,333 | 6.03 | 44,192 | 44,192 | ||
2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 988,285 | 988,285 | 6.03 | 5,955,801 | 5,955,801 | ||
2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
47,963 | ||||||||
2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
1,565,463 | ||||||||
2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
15,731 | ||||||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
J - Other | 1,193 | 1,193 | |||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Series A Preferred Stock |
J - Other | -8,346 | 0 | -100.00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -30,462 | 0 | -100.00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
J - Other | 70,042 | 70,042 | |||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Series A Preferred Stock |
J - Other | -489,320 | 0 | -100.00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1,786,012 | 0 | -100.00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 4,791 | 35,253 | 15.73 | 14.00 | 67,074 | 493,542 | |
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 30,462 | 30,462 | |||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 280,923 | 2,066,935 | 15.73 | 14.00 | 3,932,922 | 28,937,090 | |
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 1,786,012 | 1,786,012 | |||||
2013-06-25 | 3 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
21,471 | ||||||||
2013-06-24 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -114 | 38,147 | -0.30 | 5.01 | -571 | 191,116 |
2013-06-24 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -10,516 | 3,887,691 | -0.27 | 5.01 | -52,685 | 19,477,332 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -22,423 | 3,898,207 | -0.57 | 5.37 | -120,412 | 20,933,372 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -32,855 | 3,920,630 | -0.83 | 5.40 | -177,417 | 21,171,402 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -244 | 38,261 | -0.63 | 5.37 | -1,310 | 205,462 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -359 | 38,505 | -0.92 | 5.40 | -1,939 | 207,927 |
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -959 | 38,864 | -2.41 | 5.40 | -5,179 | 209,866 |
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -425 | 39,823 | -1.06 | 5.03 | -2,138 | 200,310 |
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -87,812 | 3,953,485 | -2.17 | 5.40 | -474,185 | 21,348,819 |
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -38,897 | 4,041,297 | -0.95 | 5.03 | -195,652 | 20,327,724 |
2013-06-13 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -59 | 40,248 | -0.15 | 5.00 | -295 | 201,240 |
2013-06-13 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -5,337 | 4,080,194 | -0.13 | 5.00 | -26,685 | 20,400,970 |
2013-06-06 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 35,000 | 35,000 | |||||
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -159,192 | 2,581,745 | -5.81 | 64.58 | -10,280,619 | 166,729,092 | |
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2,779 | 44,034 | -5.94 | 64.58 | -179,468 | 2,843,716 | |
2013-05-31 |
|
4 | RVA |
REVA Medical, Inc.
Stock Option (Right to Buy) |
A - Award | 15,000 | 15,000 | |||||
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -232 | 40,307 | -0.57 | 4.50 | -1,044 | 181,382 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -251 | 40,539 | -0.62 | 4.70 | -1,180 | 190,533 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -21,276 | 4,085,531 | -0.52 | 4.50 | -95,742 | 18,384,890 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -22,966 | 4,106,807 | -0.56 | 4.70 | -107,940 | 19,301,993 | |
2013-04-17 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23,210 | 2,371,190 | -0.97 | 6.62 | -153,650 | 15,697,278 |
2013-04-17 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -71,578 | 7,313,241 | -0.97 | 6.62 | -473,846 | 48,413,655 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,567 | 2,394,400 | -0.07 | 6.72 | -10,530 | 16,090,368 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11,386 | 2,395,967 | -0.47 | 6.71 | -76,400 | 16,076,939 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,217 | 2,407,353 | -0.50 | 6.52 | -79,655 | 15,695,942 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,832 | 7,384,819 | -0.07 | 6.72 | -32,471 | 49,625,984 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -35,114 | 7,389,651 | -0.47 | 6.71 | -235,615 | 49,584,558 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -37,676 | 7,424,765 | -0.50 | 6.52 | -245,648 | 48,409,468 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,374 | 2,419,570 | -0.18 | 5.35 | -23,401 | 12,944,700 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -893 | 40,484 | -2.16 | 5.49 | -4,903 | 222,257 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -13,490 | 7,462,441 | -0.18 | 5.35 | -72,172 | 39,924,059 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,743 | 78,369 | -2.18 | 5.49 | -9,569 | 430,246 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,510 | 2,423,944 | -0.23 | 5.22 | -28,762 | 12,652,988 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7,925 | 2,429,454 | -0.33 | 5.19 | -41,131 | 12,608,866 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -92 | 41,377 | -0.22 | 5.22 | -480 | 215,988 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -134 | 41,469 | -0.32 | 5.19 | -695 | 215,224 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -182 | 80,112 | -0.23 | 5.22 | -950 | 418,185 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -261 | 80,294 | -0.32 | 5.19 | -1,355 | 416,726 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16,995 | 7,475,931 | -0.23 | 5.22 | -88,714 | 39,024,360 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -24,442 | 7,492,926 | -0.33 | 5.19 | -126,854 | 38,888,286 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -8,020 | 2,437,379 | -0.33 | 5.16 | -41,383 | 12,576,876 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,636 | 2,445,399 | -0.39 | 5.28 | -50,878 | 12,911,707 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -135 | 41,603 | -0.32 | 5.16 | -697 | 214,671 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -163 | 41,738 | -0.39 | 5.28 | -861 | 220,377 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -265 | 80,555 | -0.33 | 5.16 | -1,367 | 415,664 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -318 | 80,820 | -0.39 | 5.28 | -1,679 | 426,730 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -24,736 | 7,517,368 | -0.33 | 5.16 | -127,638 | 38,789,619 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -29,719 | 7,542,104 | -0.39 | 5.28 | -156,916 | 39,822,309 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,020 | 2,455,035 | -0.20 | 5.36 | -26,907 | 13,158,988 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7,733 | 2,460,055 | -0.31 | 5.40 | -41,758 | 13,284,297 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -85 | 41,901 | -0.20 | 5.36 | -456 | 224,589 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -131 | 41,986 | -0.31 | 5.40 | -707 | 226,724 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -166 | 81,138 | -0.20 | 5.36 | -890 | 434,900 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -256 | 81,304 | -0.31 | 5.40 | -1,382 | 439,042 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,480 | 7,571,823 | -0.20 | 5.36 | -82,973 | 40,584,971 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23,848 | 7,587,303 | -0.31 | 5.40 | -128,779 | 40,971,436 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -6,346 | 2,467,788 | -0.26 | 5.38 | -34,141 | 13,276,699 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,118 | 2,474,134 | -0.17 | 5.34 | -21,990 | 13,211,876 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -107 | 42,117 | -0.25 | 5.38 | -576 | 226,589 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -70 | 42,224 | -0.17 | 5.34 | -374 | 225,476 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -210 | 81,560 | -0.26 | 5.38 | -1,130 | 438,793 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -136 | 81,770 | -0.17 | 5.34 | -726 | 436,652 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -19,569 | 7,611,151 | -0.26 | 5.38 | -105,281 | 40,947,992 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,700 | 7,630,720 | -0.17 | 5.34 | -67,818 | 40,748,045 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,154 | 2,478,252 | -0.21 | 5.32 | -27,419 | 13,184,301 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,701 | 2,483,406 | -0.51 | 5.22 | -66,299 | 12,963,379 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -88 | 42,294 | -0.21 | 5.32 | -468 | 225,004 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -215 | 42,382 | -0.50 | 5.22 | -1,122 | 221,234 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -171 | 81,906 | -0.21 | 5.32 | -910 | 435,740 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -420 | 82,077 | -0.51 | 5.22 | -2,192 | 428,442 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,892 | 7,643,420 | -0.21 | 5.32 | -84,545 | 40,662,994 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -39,168 | 7,659,312 | -0.51 | 5.22 | -204,457 | 39,981,609 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -3,839 | 2,496,107 | -0.15 | 5.06 | -19,425 | 12,630,301 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,039 | 2,499,946 | -0.16 | 5.01 | -20,235 | 12,524,729 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -65 | 42,597 | -0.15 | 5.06 | -329 | 215,541 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -69 | 42,662 | -0.16 | 5.01 | -346 | 213,737 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11,841 | 7,698,480 | -0.15 | 5.06 | -59,915 | 38,954,309 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,454 | 7,710,321 | -0.16 | 5.01 | -62,395 | 38,628,708 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -127 | 82,497 | -0.15 | 5.06 | -643 | 417,435 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -134 | 82,624 | -0.16 | 5.01 | -671 | 413,946 |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -1,651 | 46,813 | -3.41 | 24.51 | -40,466 | 1,147,387 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2,132 | 48,464 | -4.21 | 24.69 | -52,639 | 1,196,576 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -417 | 50,596 | -0.82 | 24.44 | -10,191 | 1,236,566 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -98,349 | 2,740,937 | -3.46 | 24.51 | -2,410,534 | 67,180,366 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -126,868 | 2,839,286 | -4.28 | 24.69 | -3,132,371 | 70,101,971 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -24,783 | 2,966,154 | -0.83 | 24.44 | -605,697 | 72,492,804 | |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,145 | 2,503,985 | -0.21 | 5.01 | -25,776 | 12,544,965 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7,635 | 2,509,130 | -0.30 | 5.01 | -38,251 | 12,570,741 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -88 | 42,731 | -0.21 | 5.01 | -441 | 214,082 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -130 | 42,819 | -0.30 | 5.01 | -651 | 214,523 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -170 | 82,758 | -0.20 | 5.01 | -852 | 414,618 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -253 | 82,928 | -0.30 | 5.01 | -1,268 | 415,469 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,865 | 7,722,775 | -0.21 | 5.01 | -79,484 | 38,691,103 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23,548 | 7,738,640 | -0.30 | 5.01 | -117,975 | 38,770,586 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,998 | 2,516,765 | -0.08 | 5.01 | -10,010 | 12,608,993 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -34 | 42,949 | -0.08 | 5.01 | -170 | 215,174 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -6,160 | 7,762,188 | -0.08 | 5.01 | -30,862 | 38,888,562 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -66 | 83,181 | -0.08 | 5.01 | -331 | 416,737 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -10,076 | 2,518,763 | -0.40 | 5.02 | -50,582 | 12,644,190 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -2,967 | 2,528,839 | -0.12 | 5.00 | -14,835 | 12,644,195 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -171 | 42,983 | -0.40 | 5.02 | -858 | 215,775 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51 | 43,154 | -0.12 | 5.00 | -255 | 215,770 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -334 | 83,247 | -0.40 | 5.02 | -1,677 | 417,900 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -99 | 83,581 | -0.12 | 5.00 | -495 | 417,905 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -31,075 | 7,768,348 | -0.40 | 5.02 | -155,996 | 38,997,107 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,148 | 7,799,423 | -0.12 | 5.00 | -45,740 | 38,997,115 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -2,951 | 2,531,806 | -0.12 | 5.01 | -14,785 | 12,684,348 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,763 | 2,534,757 | -0.23 | 5.00 | -28,815 | 12,673,785 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51 | 43,205 | -0.12 | 5.01 | -256 | 216,457 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -98 | 43,256 | -0.23 | 5.00 | -490 | 216,280 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -98 | 83,680 | -0.12 | 5.01 | -491 | 419,237 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -191 | 83,778 | -0.23 | 5.00 | -955 | 418,890 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,100 | 7,808,571 | -0.12 | 5.01 | -45,591 | 39,120,941 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -17,770 | 7,817,671 | -0.23 | 5.00 | -88,850 | 39,088,355 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,769 | 2,540,520 | -0.38 | 4.85 | -47,380 | 12,321,522 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -164 | 43,354 | -0.38 | 4.85 | -795 | 210,267 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -30,134 | 7,835,441 | -0.38 | 4.85 | -146,150 | 38,001,889 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -322 | 83,969 | -0.38 | 4.85 | -1,562 | 407,250 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -18,537 | 2,550,289 | -0.72 | 4.71 | -87,309 | 12,011,861 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11,105 | 2,568,826 | -0.43 | 5.00 | -55,525 | 12,844,130 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -314 | 43,518 | -0.72 | 4.71 | -1,479 | 204,970 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -188 | 43,832 | -0.43 | 5.00 | -940 | 219,160 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -57,165 | 7,865,575 | -0.72 | 4.71 | -269,247 | 37,046,858 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -34,248 | 7,922,740 | -0.43 | 5.00 | -171,240 | 39,613,700 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -613 | 84,291 | -0.72 | 4.71 | -2,887 | 397,011 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -367 | 84,904 | -0.43 | 5.00 | -1,835 | 424,520 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,320 | 2,579,931 | -0.59 | 5.27 | -80,736 | 13,596,236 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16,660 | 2,595,251 | -0.64 | 5.40 | -89,964 | 14,014,355 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -260 | 44,020 | -0.59 | 5.27 | -1,370 | 231,985 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -282 | 44,280 | -0.63 | 5.40 | -1,523 | 239,112 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -47,247 | 7,956,988 | -0.59 | 5.27 | -248,992 | 41,933,327 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51,377 | 8,004,235 | -0.64 | 5.40 | -277,436 | 43,222,869 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -507 | 85,271 | -0.59 | 5.27 | -2,672 | 449,378 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -551 | 85,778 | -0.64 | 5.40 | -2,975 | 463,201 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -13,790 | 2,611,911 | -0.53 | 5.38 | -74,190 | 14,052,081 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -36,324 | 2,625,701 | -1.36 | 5.45 | -197,966 | 14,310,070 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -234 | 44,562 | -0.52 | 5.38 | -1,259 | 239,744 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -616 | 44,796 | -1.36 | 5.45 | -3,357 | 244,138 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -456 | 86,329 | -0.53 | 5.38 | -2,453 | 464,450 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,201 | 86,785 | -1.36 | 5.45 | -6,545 | 472,978 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -42,525 | 8,055,612 | -0.53 | 5.38 | -228,784 | 43,339,193 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -111,022 | 8,098,137 | -1.35 | 5.45 | -605,070 | 44,134,847 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -25,354 | 2,662,025 | -0.94 | 5.11 | -129,559 | 13,602,948 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -14,966 | 2,687,379 | -0.55 | 5.02 | -75,129 | 13,490,643 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -430 | 45,412 | -0.94 | 5.11 | -2,197 | 232,055 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -254 | 45,842 | -0.55 | 5.02 | -1,275 | 230,127 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -839 | 87,986 | -0.94 | 5.11 | -4,287 | 449,608 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -495 | 88,825 | -0.55 | 5.02 | -2,485 | 445,902 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -78,188 | 8,210,159 | -0.94 | 5.11 | -399,541 | 41,953,912 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -46,153 | 8,288,347 | -0.55 | 5.02 | -231,688 | 41,607,502 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -19,080 | 2,702,345 | -0.70 | 5.19 | -99,025 | 14,025,171 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,615 | 2,721,425 | -0.46 | 5.35 | -67,490 | 14,559,624 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -324 | 46,096 | -0.70 | 5.19 | -1,682 | 239,238 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -214 | 46,420 | -0.46 | 5.35 | -1,145 | 248,347 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -58,838 | 8,334,500 | -0.70 | 5.19 | -305,369 | 43,256,055 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -38,903 | 8,393,338 | -0.46 | 5.35 | -208,131 | 44,904,358 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -631 | 89,320 | -0.70 | 5.19 | -3,275 | 463,571 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -418 | 89,951 | -0.46 | 5.35 | -2,236 | 481,238 |
2013-01-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 66,462 | 159,896 | 71.13 | ||||
2013-01-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1,000,000 | 5,772,968 | -14.76 | ||||
2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
2,222,175 | ||||||||
2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
16,733 | ||||||||
2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
5,868 | ||||||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -16,529 | 0 | -100.00 | ||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -2,227,596 | 0 | -100.00 | ||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
P - Purchase | 5,777 | 22,306 | 34.95 | 9.00 | 51,993 | 200,754 | |
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
C - Conversion | 16,529 | 16,529 | |||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
P - Purchase | 778,536 | 3,006,132 | 34.95 | 9.00 | 7,006,824 | 27,055,188 | |
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
C - Conversion | 2,227,596 | 2,227,596 | |||||
2012-07-18 | 3 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
6,250 | ||||||||
2012-06-12 |
|
4 | OREX |
Orexigen Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 35,000 | 35,000 | |||||
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 93,434 | 93,434 | |||||
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1,200,000 | 6,772,968 | -15.05 | ||||
2012-05-22 |
|
4 | RVA |
REVA Medical, Inc.
Stock Option (Right to Buy) |
A - Award | 12,500 | 12,500 | |||||
2012-03-27 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
S - Sale | -39,136 | 85,186 | -31.48 | 5.16 | -201,942 | 439,560 | |
2012-03-27 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
S - Sale | -1,656,581 | 3,606,002 | -31.48 | 5.16 | -8,547,958 | 18,606,970 |